Botulinum toxin type A (BTX-A) injections have emerged as a promising alternative for the management of bruxism. In this context, a systematic review of randomized controlled trials on the impact of BTX-A on patients with bruxism was conducted. A literature search of multiple online electronic databases (PubMed®, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL)) was undertaken from their inception to February 1, 2024. The Medical Subject Headings (MeSH) included "Botulinum Toxins", "Botulinum Toxins, Type A", "Bruxism", and "Sleep Bruxism", which were combined with the Boolean operators "AND" and "OR". The methodological quality of each included study was assessed using the Joanna Briggs Institute (JBI) critical appraisal tool. Reducing muscle pain and activity were assessed as primary outcomes, while the quality of sleep was considered as a secondary outcome. Twelve articles met the inclusion criteria. The risk of bias was low in 10 studies and moderate in 2. Bilateral injections of BTX-A into the masseter, temporalis and medial pterygoid muscles were compared to saline injections, the use of occlusal splints and conventional treatment. Of the 12 studies, 6 reported a reduction in muscle activity recorded by rhythmic masticatory muscle activity (RMMA) and electromyography (EMG) after the administration of BTX-A. In addition, 3 studies indicated that the intensity of muscle pain, measured using the visual analogue scale (VAS), decreased significantly in individuals with bruxism who received BTX-A. Finally, 1 study highlighted improved sleep quality in patients with bruxism who were rehabilitated with a single-arch implant overdenture and received either BTX-A or occlusal appliances. Botulinum toxin type A can effectively reduce symptoms of bruxism. However, the included studies exhibited heterogeneity and methodological differences. Long-term follow-up studies with large sample sizes and the incorporation of repeated injections are necessary to further validate the findings.

Download full-text PDF

Source
http://dx.doi.org/10.17219/dmp/186553DOI Listing

Publication Analysis

Top Keywords

botulinum toxin
12
toxin type
12
systematic review
8
controlled trials
8
patients bruxism
8
muscle pain
8
muscle activity
8
received btx-a
8
bruxism
6
btx-a
6

Similar Publications

The Role of RAC2 and PTTG1 in Cancer Biology.

Cells

February 2025

Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.

Several molecular pathways are likely involved in the regulation of cancer stem cells (CSCs) via Ras-associated C3 botulinum toxin substrate 2, RAC2, and pituitary tumor-transforming gene 1 product, PTTG1, given their roles in cellular signaling, survival, proliferation, and metastasis. RAC2 is a member of the Rho GTPase family and plays a crucial role in actin cytoskeleton dynamics, reactive oxygen species production, and cell migration, contributing to epithelial-mesenchymal transition (EMT), immune evasion, and therapy resistance. PTTG1, also known as human securin, regulates key processes such as cell cycle progression, apoptosis suppression, and EMT, promoting metastasis and enhancing cancer cell survival.

View Article and Find Full Text PDF

Botulinum neurotoxin (BoNT) is a highly lethal toxin produced by the anaerobic bacterium Clostridium botulinum, which leads to nerve paralysis following poisoning. At present, there is no specific drug officially approved. Antibodies, particularly single-domain antibodies, represent safe and effective candidates for specific drugs against BoNT.

View Article and Find Full Text PDF

A Review on the Expanding Role of Dentists in Facial Esthetics.

J Pharm Bioallied Sci

December 2024

Department of Clinical Dental Sciences, Ajman University, Ajman, United Arab Emirates.

Dentists' role in facial esthetics is growing, with advancements in cosmetic procedures, such as Botox and dermal fillers. Understanding the range of practitioners and their professional backgrounds is crucial for addressing risks. Data collection and analysis was done to retrieve scholarly papers using databases, such as PubMed and advanced Google search, and analyze.

View Article and Find Full Text PDF

Medication and Therapy Profiles for Pain and Symptom Management Among Adults With Cerebral Palsy.

Mayo Clin Proc Innov Qual Outcomes

April 2025

Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI.

Objective: To examine the most common patterns of pain and symptom management strategies among adults living with cerebral palsy (CP), and to determine if there are differences by pain phenotype or co-occurring neurodevelopmental disorders.

Patients And Methods: Federally insured beneficiaries were included if they had an ICD-9-CM/ICD-10-CM diagnosis code for CP (N=41,595). The study took place from January 10, 2024, to December 15, 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!